1 – 10 of 13
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer : Data from the Swedish TP53 Study
2023) In Cancer(
- Contribution to journal › Article
- 2022
-
Mark
Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)
(
- Contribution to journal › Article
-
Mark
Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed : The Study Protocol for the Randomized Controlled NEEDS Trial
(
- Contribution to journal › Article
- 2021
-
Mark
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients with ERBB2-Positive Breast Cancer : A Phase 2 Randomized Clinical Trial
(
- Contribution to journal › Article
- 2020
-
Mark
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer : Results from the phase 3 PANTHER trial
(
- Contribution to journal › Article
- 2019
-
Mark
First line therapy in chronic lymphocytic leukemia : a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
(
- Contribution to journal › Article
-
Mark
Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ
(
- Contribution to journal › Article
- 2018
-
Mark
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
(
- Contribution to journal › Article
- 2017
-
Mark
Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection : The randomized controlled SENOMAC trial
(
- Contribution to journal › Article
-
Mark
Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III) : A multicentre, randomised, non-blinded, phase 3, non-inferiority trial
(
- Contribution to journal › Article